Bio-Rad Laboratories, Inc. (NYSE: BIO-B) Stock Competitors & Peer Comparison
See BIO-B's competitors and their performance on the NYSE and across the wider stock market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for BIO-B and its NYSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| BIO-B | $381.37 | +4.46% | 10.4B | -67.15 | -$5.68 | N/A |
| ABT | $110.47 | +1.41% | 191.2B | 21.20 | $5.21 | +2.24% |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| SYK | $312.19 | -1.64% | 119.7B | 23.32 | $13.39 | +1.11% |
| MDT | $92.18 | +0.15% | 118B | 16.67 | $5.53 | +3.07% |
| BSX | $48.37 | +0.59% | 71.9B | 15.60 | $3.10 | N/A |
| EW | $90.82 | +0.09% | 52.3B | 33.64 | $2.70 | N/A |
| DXCM | $89.69 | -0.50% | 33.8B | 35.17 | $2.55 | N/A |
| GEHC | $70.56 | +0.20% | 31.9B | 15.47 | $4.56 | +0.20% |
| PHG | $26.37 | -0.83% | 25.8B | 15.08 | $1.75 | +3.75% |
Stock Comparison
Abbott Laboratories (NYSE: ABT)
BIO-B vs ABT Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, ABT has a market cap of 191.2B. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while ABT trades at $110.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas ABT's P/E ratio is 21.20. In terms of profitability, BIO-B's ROE is +0.03%, compared to ABT's ROE of +0.11%. Regarding short-term risk, BIO-B is less volatile compared to ABT. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check ABT's competition here
Boston Scientific Corporation (NYSE: BSX-PA)
BIO-B vs BSX-PA Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, BIO-B's ROE is +0.03%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, BIO-B is less volatile compared to BSX-PA. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check BSX-PA's competition here
Stryker Corporation (NYSE: SYK)
BIO-B vs SYK Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, SYK has a market cap of 119.7B. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while SYK trades at $312.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas SYK's P/E ratio is 23.32. In terms of profitability, BIO-B's ROE is +0.03%, compared to SYK's ROE of +0.16%. Regarding short-term risk, BIO-B is less volatile compared to SYK. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check SYK's competition here
Medtronic plc (NYSE: MDT)
BIO-B vs MDT Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, MDT has a market cap of 118B. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while MDT trades at $92.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas MDT's P/E ratio is 16.67. In terms of profitability, BIO-B's ROE is +0.03%, compared to MDT's ROE of +0.14%. Regarding short-term risk, BIO-B is less volatile compared to MDT. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check MDT's competition here
Boston Scientific Corporation (NYSE: BSX)
BIO-B vs BSX Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, BSX has a market cap of 71.9B. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while BSX trades at $48.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas BSX's P/E ratio is 15.60. In terms of profitability, BIO-B's ROE is +0.03%, compared to BSX's ROE of +0.15%. Regarding short-term risk, BIO-B is less volatile compared to BSX. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check BSX's competition here
Edwards Lifesciences Corporation (NYSE: EW)
BIO-B vs EW Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, EW has a market cap of 52.3B. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while EW trades at $90.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas EW's P/E ratio is 33.64. In terms of profitability, BIO-B's ROE is +0.03%, compared to EW's ROE of +0.10%. Regarding short-term risk, BIO-B is less volatile compared to EW. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check EW's competition here
DexCom, Inc. (NASDAQ: DXCM)
BIO-B vs DXCM Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, DXCM has a market cap of 33.8B. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while DXCM trades at $89.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas DXCM's P/E ratio is 35.17. In terms of profitability, BIO-B's ROE is +0.03%, compared to DXCM's ROE of +0.36%. Regarding short-term risk, BIO-B is less volatile compared to DXCM. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check DXCM's competition here
GE HealthCare Technologies Inc. (NASDAQ: GEHC)
BIO-B vs GEHC Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, GEHC has a market cap of 31.9B. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while GEHC trades at $70.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas GEHC's P/E ratio is 15.47. In terms of profitability, BIO-B's ROE is +0.03%, compared to GEHC's ROE of +0.15%. Regarding short-term risk, BIO-B is less volatile compared to GEHC. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check GEHC's competition here
Koninklijke Philips N.V. (NYSE: PHG)
BIO-B vs PHG Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, PHG has a market cap of 25.8B. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while PHG trades at $26.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas PHG's P/E ratio is 15.08. In terms of profitability, BIO-B's ROE is +0.03%, compared to PHG's ROE of +0.10%. Regarding short-term risk, BIO-B is less volatile compared to PHG. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check PHG's competition here
Zimmer Biomet Holdings, Inc. (NYSE: ZBH)
BIO-B vs ZBH Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, ZBH has a market cap of 19.3B. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while ZBH trades at $99.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas ZBH's P/E ratio is 11.73. In terms of profitability, BIO-B's ROE is +0.03%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, BIO-B is less volatile compared to ZBH. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check ZBH's competition here
Abiomed, Inc. (NASDAQ: ABMD)
BIO-B vs ABMD Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas ABMD's P/E ratio is 65.36. In terms of profitability, BIO-B's ROE is +0.03%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, BIO-B is less volatile compared to ABMD. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check ABMD's competition here
Penumbra, Inc. (NYSE: PEN)
BIO-B vs PEN Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, PEN has a market cap of 12.7B. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while PEN trades at $322.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas PEN's P/E ratio is 84.30. In terms of profitability, BIO-B's ROE is +0.03%, compared to PEN's ROE of +0.11%. Regarding short-term risk, BIO-B is less volatile compared to PEN. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check PEN's competition here
ShockWave Medical, Inc. (NASDAQ: SWAV)
BIO-B vs SWAV Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas SWAV's P/E ratio is 78.76. In terms of profitability, BIO-B's ROE is +0.03%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, BIO-B is more volatile compared to SWAV. This indicates higher risk in terms of short-term price fluctuations for BIO-B.Check SWAV's competition here
Smith & Nephew plc (NYSE: SNN)
BIO-B vs SNN Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, SNN has a market cap of 12B. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while SNN trades at $28.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas SNN's P/E ratio is 13.49. In terms of profitability, BIO-B's ROE is +0.03%, compared to SNN's ROE of +0.12%. Regarding short-term risk, BIO-B is less volatile compared to SNN. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check SNN's competition here
Align Technology, Inc. (NASDAQ: ALGN)
BIO-B vs ALGN Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, ALGN has a market cap of 11.4B. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while ALGN trades at $159.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas ALGN's P/E ratio is 14.51. In terms of profitability, BIO-B's ROE is +0.03%, compared to ALGN's ROE of +0.10%. Regarding short-term risk, BIO-B is less volatile compared to ALGN. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check ALGN's competition here
Globus Medical, Inc. (NYSE: GMED)
BIO-B vs GMED Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, GMED has a market cap of 10.9B. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while GMED trades at $80.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas GMED's P/E ratio is 18.17. In terms of profitability, BIO-B's ROE is +0.03%, compared to GMED's ROE of +0.12%. Regarding short-term risk, BIO-B is less volatile compared to GMED. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check GMED's competition here
Glaukos Corporation (NYSE: GKOS)
BIO-B vs GKOS Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, GKOS has a market cap of 10.6B. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while GKOS trades at $179.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas GKOS's P/E ratio is -208.69. In terms of profitability, BIO-B's ROE is +0.03%, compared to GKOS's ROE of -0.27%. Regarding short-term risk, BIO-B is less volatile compared to GKOS. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check GKOS's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO)
BIO-B vs BIO Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, BIO has a market cap of 10.5B. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while BIO trades at $388.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas BIO's P/E ratio is 41.86. In terms of profitability, BIO-B's ROE is +0.03%, compared to BIO's ROE of +0.03%. Regarding short-term risk, BIO-B is less volatile compared to BIO. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check BIO's competition here
Insulet Corp. (NASDAQ: PODD)
BIO-B vs PODD Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, PODD has a market cap of 10.3B. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while PODD trades at $148.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas PODD's P/E ratio is 25.24. In terms of profitability, BIO-B's ROE is +0.03%, compared to PODD's ROE of +0.27%. Regarding short-term risk, BIO-B is less volatile compared to PODD. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check PODD's competition here
Masimo Corporation (NASDAQ: MASI)
BIO-B vs MASI Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while MASI trades at $179.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas MASI's P/E ratio is 44.43. In terms of profitability, BIO-B's ROE is +0.03%, compared to MASI's ROE of +0.09%. Regarding short-term risk, BIO-B is more volatile compared to MASI. This indicates higher risk in terms of short-term price fluctuations for BIO-B.Check MASI's competition here
Bruker Corporation (NASDAQ: BRKR)
BIO-B vs BRKR Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, BRKR has a market cap of 9B. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while BRKR trades at $59.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas BRKR's P/E ratio is 29.66. In terms of profitability, BIO-B's ROE is +0.03%, compared to BRKR's ROE of -0.03%. Regarding short-term risk, BIO-B is less volatile compared to BRKR. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check BRKR's competition here
Bruker Corporation (NASDAQ: BRKRP)
BIO-B vs BRKRP Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, BRKRP has a market cap of 8.7B. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while BRKRP trades at $435.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas BRKRP's P/E ratio is 236.70. In terms of profitability, BIO-B's ROE is +0.03%, compared to BRKRP's ROE of -0.03%. Regarding short-term risk, BIO-B is less volatile compared to BRKRP. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check BRKRP's competition here
Inari Medical, Inc. (NASDAQ: NARI)
BIO-B vs NARI Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas NARI's P/E ratio is -59.24. In terms of profitability, BIO-B's ROE is +0.03%, compared to NARI's ROE of -0.00%. Regarding short-term risk, BIO-B is more volatile compared to NARI. This indicates higher risk in terms of short-term price fluctuations for BIO-B.Check NARI's competition here
Haemonetics Corporation (NYSE: HAE)
BIO-B vs HAE Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, HAE has a market cap of 4.7B. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while HAE trades at $102.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas HAE's P/E ratio is 20.56. In terms of profitability, BIO-B's ROE is +0.03%, compared to HAE's ROE of +0.11%. Regarding short-term risk, BIO-B is less volatile compared to HAE. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check HAE's competition here
LivaNova PLC (NASDAQ: LIVN)
BIO-B vs LIVN Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, LIVN has a market cap of 4.5B. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while LIVN trades at $82.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas LIVN's P/E ratio is 19.57. In terms of profitability, BIO-B's ROE is +0.03%, compared to LIVN's ROE of +0.15%. Regarding short-term risk, BIO-B is less volatile compared to LIVN. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check LIVN's competition here
Integer Holdings Corporation (NYSE: ITGR)
BIO-B vs ITGR Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, ITGR has a market cap of 4.3B. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while ITGR trades at $125.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas ITGR's P/E ratio is 19.73. In terms of profitability, BIO-B's ROE is +0.03%, compared to ITGR's ROE of +0.07%. Regarding short-term risk, BIO-B is more volatile compared to ITGR. This indicates higher risk in terms of short-term price fluctuations for BIO-B.Check ITGR's competition here
iRhythm Technologies, Inc. (NASDAQ: IRTC)
BIO-B vs IRTC Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, IRTC has a market cap of 4B. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while IRTC trades at $122.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas IRTC's P/E ratio is -284.85. In terms of profitability, BIO-B's ROE is +0.03%, compared to IRTC's ROE of -0.09%. Regarding short-term risk, BIO-B is less volatile compared to IRTC. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check IRTC's competition here
Axonics, Inc. (NASDAQ: AXNX)
BIO-B vs AXNX Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas AXNX's P/E ratio is -709.80. In terms of profitability, BIO-B's ROE is +0.03%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, BIO-B is more volatile compared to AXNX. This indicates higher risk in terms of short-term price fluctuations for BIO-B.Check AXNX's competition here
TransMedics Group, Inc. (NASDAQ: TMDX)
BIO-B vs TMDX Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, TMDX has a market cap of 2.9B. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while TMDX trades at $84.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas TMDX's P/E ratio is 42.79. In terms of profitability, BIO-B's ROE is +0.03%, compared to TMDX's ROE of +0.33%. Regarding short-term risk, BIO-B is less volatile compared to TMDX. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check TMDX's competition here
AxoGen, Inc. (NASDAQ: AXGN)
BIO-B vs AXGN Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, AXGN has a market cap of 2.6B. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while AXGN trades at $48.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas AXGN's P/E ratio is 127.11. In terms of profitability, BIO-B's ROE is +0.03%, compared to AXGN's ROE of -0.18%. Regarding short-term risk, BIO-B is less volatile compared to AXGN. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check AXGN's competition here
Neogen Corporation (NASDAQ: NEOG)
BIO-B vs NEOG Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, NEOG has a market cap of 2.6B. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while NEOG trades at $11.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas NEOG's P/E ratio is 42.18. In terms of profitability, BIO-B's ROE is +0.03%, compared to NEOG's ROE of -0.00%. Regarding short-term risk, BIO-B is less volatile compared to NEOG. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check NEOG's competition here
UFP Technologies, Inc. (NASDAQ: UFPT)
BIO-B vs UFPT Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, UFPT has a market cap of 2.3B. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while UFPT trades at $292.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas UFPT's P/E ratio is 29.87. In terms of profitability, BIO-B's ROE is +0.03%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, BIO-B is less volatile compared to UFPT. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check UFPT's competition here
Establishment Labs Holdings Inc. (NASDAQ: ESTA)
BIO-B vs ESTA Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, ESTA has a market cap of 2.2B. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while ESTA trades at $74.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas ESTA's P/E ratio is -59.46. In terms of profitability, BIO-B's ROE is +0.03%, compared to ESTA's ROE of -2.04%. Regarding short-term risk, BIO-B is less volatile compared to ESTA. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check ESTA's competition here
NuVasive, Inc. (NASDAQ: NUVA)
BIO-B vs NUVA Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas NUVA's P/E ratio is 75.00. In terms of profitability, BIO-B's ROE is +0.03%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, BIO-B is less volatile compared to NUVA. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check NUVA's competition here
Novocure Ltd (NASDAQ: NVCR)
BIO-B vs NVCR Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, NVCR has a market cap of 2.1B. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while NVCR trades at $17.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas NVCR's P/E ratio is -13.72. In terms of profitability, BIO-B's ROE is +0.03%, compared to NVCR's ROE of -0.44%. Regarding short-term risk, BIO-B is less volatile compared to NVCR. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check NVCR's competition here
Butterfly Network, Inc. (NYSE: BFLY)
BIO-B vs BFLY Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, BFLY has a market cap of 2B. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while BFLY trades at $7.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas BFLY's P/E ratio is -31.69. In terms of profitability, BIO-B's ROE is +0.03%, compared to BFLY's ROE of -0.38%. Regarding short-term risk, BIO-B is less volatile compared to BFLY. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check BFLY's competition here
Inspire Medical Systems, Inc. (NYSE: INSP)
BIO-B vs INSP Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, INSP has a market cap of 1.8B. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while INSP trades at $63.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas INSP's P/E ratio is 27.80. In terms of profitability, BIO-B's ROE is +0.03%, compared to INSP's ROE of +0.18%. Regarding short-term risk, BIO-B is less volatile compared to INSP. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check INSP's competition here
CONMED Corporation (NYSE: CNMD)
BIO-B vs CNMD Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, CNMD has a market cap of 1.5B. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while CNMD trades at $49.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas CNMD's P/E ratio is 10.86. In terms of profitability, BIO-B's ROE is +0.03%, compared to CNMD's ROE of +0.06%. Regarding short-term risk, BIO-B is less volatile compared to CNMD. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check CNMD's competition here
Alphatec Holdings, Inc. (NASDAQ: ATEC)
BIO-B vs ATEC Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, ATEC has a market cap of 1.4B. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while ATEC trades at $9.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas ATEC's P/E ratio is -153.17. In terms of profitability, BIO-B's ROE is +0.03%, compared to ATEC's ROE of -8.19%. Regarding short-term risk, BIO-B is less volatile compared to ATEC. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check ATEC's competition here
Tandem Diabetes Care, Inc. (NASDAQ: TNDM)
BIO-B vs TNDM Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, TNDM has a market cap of 1.4B. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while TNDM trades at $20.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas TNDM's P/E ratio is -22.11. In terms of profitability, BIO-B's ROE is +0.03%, compared to TNDM's ROE of -0.46%. Regarding short-term risk, BIO-B is less volatile compared to TNDM. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check TNDM's competition here
Heska Corporation (NASDAQ: HSKA)
BIO-B vs HSKA Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas HSKA's P/E ratio is -62.49. In terms of profitability, BIO-B's ROE is +0.03%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, BIO-B is more volatile compared to HSKA. This indicates higher risk in terms of short-term price fluctuations for BIO-B.Check HSKA's competition here
Integra LifeSciences Holdings Corporation (NASDAQ: IART)
BIO-B vs IART Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, IART has a market cap of 1.3B. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while IART trades at $16.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas IART's P/E ratio is 7.12. In terms of profitability, BIO-B's ROE is +0.03%, compared to IART's ROE of -0.01%. Regarding short-term risk, BIO-B is less volatile compared to IART. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check IART's competition here
Artivion, Inc. (NYSE: AORT)
BIO-B vs AORT Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, AORT has a market cap of 1.3B. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while AORT trades at $26.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas AORT's P/E ratio is 43.85. In terms of profitability, BIO-B's ROE is +0.03%, compared to AORT's ROE of -0.01%. Regarding short-term risk, BIO-B is less volatile compared to AORT. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check AORT's competition here
PROCEPT BioRobotics Corporation (NASDAQ: PRCT)
BIO-B vs PRCT Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, PRCT has a market cap of 1.3B. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while PRCT trades at $21.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas PRCT's P/E ratio is -11.32. In terms of profitability, BIO-B's ROE is +0.03%, compared to PRCT's ROE of -0.31%. Regarding short-term risk, BIO-B is less volatile compared to PRCT. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check PRCT's competition here
Avanos Medical, Inc. (NYSE: AVNS)
BIO-B vs AVNS Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while AVNS trades at $24.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas AVNS's P/E ratio is 27.77. In terms of profitability, BIO-B's ROE is +0.03%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, BIO-B is more volatile compared to AVNS. This indicates higher risk in terms of short-term price fluctuations for BIO-B.Check AVNS's competition here
Enovis Corporation (NYSE: ENOV)
BIO-B vs ENOV Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, ENOV has a market cap of 1.2B. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while ENOV trades at $20.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas ENOV's P/E ratio is 5.79. In terms of profitability, BIO-B's ROE is +0.03%, compared to ENOV's ROE of -0.68%. Regarding short-term risk, BIO-B is less volatile compared to ENOV. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check ENOV's competition here
Lumexa Imaging Holdings, Inc. Common Stock (NASDAQ: LMRI)
BIO-B vs LMRI Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, LMRI has a market cap of 1.1B. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while LMRI trades at $11.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas LMRI's P/E ratio is -22.86. In terms of profitability, BIO-B's ROE is +0.03%, compared to LMRI's ROE of -0.06%. Regarding short-term risk, BIO-B is less volatile compared to LMRI. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check LMRI's competition here
Silk Road Medical, Inc (NASDAQ: SILK)
BIO-B vs SILK Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas SILK's P/E ratio is -18.96. In terms of profitability, BIO-B's ROE is +0.03%, compared to SILK's ROE of -0.35%. Regarding short-term risk, BIO-B is more volatile compared to SILK. This indicates higher risk in terms of short-term price fluctuations for BIO-B.Check SILK's competition here
IRadimed Corporation (NASDAQ: IRMD)
BIO-B vs IRMD Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, IRMD has a market cap of 1.1B. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while IRMD trades at $86.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas IRMD's P/E ratio is 43.30. In terms of profitability, BIO-B's ROE is +0.03%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, BIO-B is less volatile compared to IRMD. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check IRMD's competition here
Paragon 28, Inc. (NYSE: FNA)
BIO-B vs FNA Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas FNA's P/E ratio is -19.83. In terms of profitability, BIO-B's ROE is +0.03%, compared to FNA's ROE of -0.35%. Regarding short-term risk, BIO-B is less volatile compared to FNA. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check FNA's competition here
Bioventus Inc. (NASDAQ: BVS)
BIO-B vs BVS Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, BVS has a market cap of 973.5M. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while BVS trades at $14.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas BVS's P/E ratio is 18.91. In terms of profitability, BIO-B's ROE is +0.03%, compared to BVS's ROE of +0.28%. Regarding short-term risk, BIO-B is less volatile compared to BVS. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check BVS's competition here
CeriBell, Inc. (NASDAQ: CBLL)
BIO-B vs CBLL Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, CBLL has a market cap of 941.4M. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while CBLL trades at $24.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas CBLL's P/E ratio is -14.10. In terms of profitability, BIO-B's ROE is +0.03%, compared to CBLL's ROE of -0.45%. Regarding short-term risk, BIO-B is less volatile compared to CBLL. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check CBLL's competition here
Beta Bionics, Inc. (NASDAQ: BBNX)
BIO-B vs BBNX Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, BBNX has a market cap of 873.5M. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while BBNX trades at $19.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas BBNX's P/E ratio is -11.77. In terms of profitability, BIO-B's ROE is +0.03%, compared to BBNX's ROE of -0.26%. Regarding short-term risk, BIO-B is less volatile compared to BBNX. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check BBNX's competition here
InMode Ltd. (NASDAQ: INMD)
BIO-B vs INMD Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, INMD has a market cap of 859.3M. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while INMD trades at $14.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas INMD's P/E ratio is 10.38. In terms of profitability, BIO-B's ROE is +0.03%, compared to INMD's ROE of +0.12%. Regarding short-term risk, BIO-B is less volatile compared to INMD. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check INMD's competition here
SI-BONE, Inc. (NASDAQ: SIBN)
BIO-B vs SIBN Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, SIBN has a market cap of 849.7M. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while SIBN trades at $19.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas SIBN's P/E ratio is -56.35. In terms of profitability, BIO-B's ROE is +0.03%, compared to SIBN's ROE of -0.08%. Regarding short-term risk, BIO-B is less volatile compared to SIBN. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check SIBN's competition here
Cardiovascular Systems, Inc. (NASDAQ: CSII)
BIO-B vs CSII Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, CSII has a market cap of 844M. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas CSII's P/E ratio is -20.83. In terms of profitability, BIO-B's ROE is +0.03%, compared to CSII's ROE of -0.14%. Regarding short-term risk, BIO-B is more volatile compared to CSII. This indicates higher risk in terms of short-term price fluctuations for BIO-B.Check CSII's competition here
Anteris Technologies Global Corp. (NASDAQ: AVR)
BIO-B vs AVR Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, AVR has a market cap of 835.2M. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while AVR trades at $8.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas AVR's P/E ratio is -4.43. In terms of profitability, BIO-B's ROE is +0.03%, compared to AVR's ROE of -0.78%. Regarding short-term risk, BIO-B is less volatile compared to AVR. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check AVR's competition here
AdaptHealth Corp. (NASDAQ: AHCO)
BIO-B vs AHCO Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, AHCO has a market cap of 821.8M. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while AHCO trades at $6.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas AHCO's P/E ratio is 12.33. In terms of profitability, BIO-B's ROE is +0.03%, compared to AHCO's ROE of -0.15%. Regarding short-term risk, BIO-B is less volatile compared to AHCO. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check AHCO's competition here
Varex Imaging Corporation (NASDAQ: VREX)
BIO-B vs VREX Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, VREX has a market cap of 777.6M. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while VREX trades at $18.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas VREX's P/E ratio is 19.44. In terms of profitability, BIO-B's ROE is +0.03%, compared to VREX's ROE of +0.05%. Regarding short-term risk, BIO-B is more volatile compared to VREX. This indicates higher risk in terms of short-term price fluctuations for BIO-B.Check VREX's competition here
SS Innovations International, Inc. (NASDAQ: SSII)
BIO-B vs SSII Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, SSII has a market cap of 680.4M. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while SSII trades at $3.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas SSII's P/E ratio is -66.32. In terms of profitability, BIO-B's ROE is +0.03%, compared to SSII's ROE of -0.27%. Regarding short-term risk, BIO-B is less volatile compared to SSII. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check SSII's competition here
Surmodics, Inc. (NASDAQ: SRDX)
BIO-B vs SRDX Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while SRDX trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas SRDX's P/E ratio is -34.66. In terms of profitability, BIO-B's ROE is +0.03%, compared to SRDX's ROE of -0.10%. Regarding short-term risk, BIO-B is more volatile compared to SRDX. This indicates higher risk in terms of short-term price fluctuations for BIO-B.Check SRDX's competition here
Cytek Biosciences, Inc. (NASDAQ: CTKB)
BIO-B vs CTKB Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, CTKB has a market cap of 605.7M. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while CTKB trades at $4.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas CTKB's P/E ratio is -24.85. In terms of profitability, BIO-B's ROE is +0.03%, compared to CTKB's ROE of -0.24%. Regarding short-term risk, BIO-B is less volatile compared to CTKB. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check CTKB's competition here
OrthoPediatrics Corp. (NASDAQ: KIDS)
BIO-B vs KIDS Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, KIDS has a market cap of 585.6M. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while KIDS trades at $22.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas KIDS's P/E ratio is -19.32. In terms of profitability, BIO-B's ROE is +0.03%, compared to KIDS's ROE of -0.12%. Regarding short-term risk, BIO-B is less volatile compared to KIDS. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check KIDS's competition here
Apollo Endosurgery, Inc. (NASDAQ: APEN)
BIO-B vs APEN Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas APEN's P/E ratio is -9.43. In terms of profitability, BIO-B's ROE is +0.03%, compared to APEN's ROE of -0.85%. Regarding short-term risk, BIO-B is less volatile compared to APEN. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check APEN's competition here
Delcath Systems, Inc. (NASDAQ: DCTH)
BIO-B vs DCTH Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, DCTH has a market cap of 572.4M. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while DCTH trades at $16.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas DCTH's P/E ratio is 1658.00. In terms of profitability, BIO-B's ROE is +0.03%, compared to DCTH's ROE of +0.00%. Regarding short-term risk, BIO-B is less volatile compared to DCTH. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check DCTH's competition here
ZimVie Inc. (NASDAQ: ZIMV)
BIO-B vs ZIMV Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, BIO-B's ROE is +0.03%, compared to ZIMV's ROE of -0.01%. Regarding short-term risk, BIO-B is more volatile compared to ZIMV. This indicates higher risk in terms of short-term price fluctuations for BIO-B.Check ZIMV's competition here
Cerus Corporation (NASDAQ: CERS)
BIO-B vs CERS Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, CERS has a market cap of 524M. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while CERS trades at $2.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas CERS's P/E ratio is -51.90. In terms of profitability, BIO-B's ROE is +0.03%, compared to CERS's ROE of -0.10%. Regarding short-term risk, BIO-B is less volatile compared to CERS. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check CERS's competition here
NeuroPace, Inc. (NASDAQ: NPCE)
BIO-B vs NPCE Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, NPCE has a market cap of 517.9M. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while NPCE trades at $15.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas NPCE's P/E ratio is -26.65. In terms of profitability, BIO-B's ROE is +0.03%, compared to NPCE's ROE of -1.20%. Regarding short-term risk, BIO-B is less volatile compared to NPCE. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check NPCE's competition here
Tactile Systems Technology, Inc. (NASDAQ: TCMD)
BIO-B vs TCMD Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, TCMD has a market cap of 505.5M. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while TCMD trades at $22.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas TCMD's P/E ratio is 20.75. In terms of profitability, BIO-B's ROE is +0.03%, compared to TCMD's ROE of +0.11%. Regarding short-term risk, BIO-B is less volatile compared to TCMD. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check TCMD's competition here
Sight Sciences, Inc. (NASDAQ: SGHT)
BIO-B vs SGHT Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, SGHT has a market cap of 458.1M. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while SGHT trades at $8.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas SGHT's P/E ratio is -15.04. In terms of profitability, BIO-B's ROE is +0.03%, compared to SGHT's ROE of -0.51%. Regarding short-term risk, BIO-B is less volatile compared to SGHT. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check SGHT's competition here
Carlsmed, Inc. (NASDAQ: CARL)
BIO-B vs CARL Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, CARL has a market cap of 444.2M. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while CARL trades at $16.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas CARL's P/E ratio is -11.43. In terms of profitability, BIO-B's ROE is +0.03%, compared to CARL's ROE of -0.38%. Regarding short-term risk, BIO-B is less volatile compared to CARL. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check CARL's competition here
ClearPoint Neuro, Inc. (NASDAQ: CLPT)
BIO-B vs CLPT Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, CLPT has a market cap of 429.2M. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while CLPT trades at $14.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas CLPT's P/E ratio is -12.13. In terms of profitability, BIO-B's ROE is +0.03%, compared to CLPT's ROE of -1.88%. Regarding short-term risk, BIO-B is less volatile compared to CLPT. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check CLPT's competition here
Senseonics Holdings, Inc. (NASDAQ: SENS)
BIO-B vs SENS Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, SENS has a market cap of 415.4M. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while SENS trades at $9.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas SENS's P/E ratio is -4.46. In terms of profitability, BIO-B's ROE is +0.03%, compared to SENS's ROE of -1.66%. Regarding short-term risk, BIO-B is less volatile compared to SENS. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check SENS's competition here
Pacific Biosciences of California, Inc. (NASDAQ: PACB)
BIO-B vs PACB Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, PACB has a market cap of 410M. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while PACB trades at $1.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas PACB's P/E ratio is -3.22. In terms of profitability, BIO-B's ROE is +0.03%, compared to PACB's ROE of -49.62%. Regarding short-term risk, BIO-B is less volatile compared to PACB. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check PACB's competition here
Orthofix Medical Inc. (NASDAQ: OFIX)
BIO-B vs OFIX Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, OFIX has a market cap of 379.2M. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while OFIX trades at $9.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas OFIX's P/E ratio is -6.11. In terms of profitability, BIO-B's ROE is +0.03%, compared to OFIX's ROE of -0.14%. Regarding short-term risk, BIO-B is less volatile compared to OFIX. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check OFIX's competition here
Perspective Therapeutics, Inc. (AMEX: CATX)
BIO-B vs CATX Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, CATX has a market cap of 354.1M. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while CATX trades at $3.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas CATX's P/E ratio is -2.33. In terms of profitability, BIO-B's ROE is +0.03%, compared to CATX's ROE of -0.42%. Regarding short-term risk, BIO-B is less volatile compared to CATX. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check CATX's competition here
TriSalus Life Sciences, Inc. (NASDAQ: TLSI)
BIO-B vs TLSI Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, TLSI has a market cap of 316.5M. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while TLSI trades at $5.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas TLSI's P/E ratio is -3.06. In terms of profitability, BIO-B's ROE is +0.03%, compared to TLSI's ROE of +2.74%. Regarding short-term risk, BIO-B is less volatile compared to TLSI. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check TLSI's competition here
Semler Scientific, Inc. (NASDAQ: SMLR)
BIO-B vs SMLR Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas SMLR's P/E ratio is 3.92. In terms of profitability, BIO-B's ROE is +0.03%, compared to SMLR's ROE of +0.06%. Regarding short-term risk, BIO-B is more volatile compared to SMLR. This indicates higher risk in terms of short-term price fluctuations for BIO-B.Check SMLR's competition here
Treace Medical Concepts, Inc. (NASDAQ: TMCI)
BIO-B vs TMCI Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, TMCI has a market cap of 304.9M. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while TMCI trades at $4.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas TMCI's P/E ratio is -5.00. In terms of profitability, BIO-B's ROE is +0.03%, compared to TMCI's ROE of -0.74%. Regarding short-term risk, BIO-B is less volatile compared to TMCI. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check TMCI's competition here
CapsoVision, Inc. (NASDAQ: CV)
BIO-B vs CV Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, CV has a market cap of 296.3M. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while CV trades at $5.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas CV's P/E ratio is -2.37. In terms of profitability, BIO-B's ROE is +0.03%, compared to CV's ROE of -1.78%. Regarding short-term risk, BIO-B is less volatile compared to CV. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check CV's competition here
RxSight, Inc. (NASDAQ: RXST)
BIO-B vs RXST Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, RXST has a market cap of 291M. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while RXST trades at $7.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas RXST's P/E ratio is -6.22. In terms of profitability, BIO-B's ROE is +0.03%, compared to RXST's ROE of -0.17%. Regarding short-term risk, BIO-B is less volatile compared to RXST. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check RXST's competition here
Avita Medical Inc. (NASDAQ: RCEL)
BIO-B vs RCEL Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, RCEL has a market cap of 267.3M. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while RCEL trades at $10.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas RCEL's P/E ratio is -7.47. In terms of profitability, BIO-B's ROE is +0.03%, compared to RCEL's ROE of +2.32%. Regarding short-term risk, BIO-B is less volatile compared to RCEL. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check RCEL's competition here
Profound Medical Corp. (NASDAQ: PROF)
BIO-B vs PROF Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, PROF has a market cap of 247.8M. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while PROF trades at $6.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas PROF's P/E ratio is -6.96. In terms of profitability, BIO-B's ROE is +0.03%, compared to PROF's ROE of -0.56%. Regarding short-term risk, BIO-B is less volatile compared to PROF. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check PROF's competition here
InfuSystem Holdings, Inc. (AMEX: INFU)
BIO-B vs INFU Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, INFU has a market cap of 245.4M. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while INFU trades at $12.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas INFU's P/E ratio is 29.66. In terms of profitability, BIO-B's ROE is +0.03%, compared to INFU's ROE of +0.15%. Regarding short-term risk, BIO-B is less volatile compared to INFU. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check INFU's competition here
Monogram Orthopaedics, Inc. (NASDAQ: MGRM)
BIO-B vs MGRM Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas MGRM's P/E ratio is -12.00. In terms of profitability, BIO-B's ROE is +0.03%, compared to MGRM's ROE of -0.85%. Regarding short-term risk, BIO-B is more volatile compared to MGRM. This indicates higher risk in terms of short-term price fluctuations for BIO-B.Check MGRM's competition here
Electromed, Inc. (AMEX: ELMD)
BIO-B vs ELMD Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, ELMD has a market cap of 234.6M. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while ELMD trades at $28.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas ELMD's P/E ratio is 21.63. In terms of profitability, BIO-B's ROE is +0.03%, compared to ELMD's ROE of +0.23%. Regarding short-term risk, BIO-B is less volatile compared to ELMD. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check ELMD's competition here
Nevro Corp. (NYSE: NVRO)
BIO-B vs NVRO Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas NVRO's P/E ratio is -1.91. In terms of profitability, BIO-B's ROE is +0.03%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, BIO-B is less volatile compared to NVRO. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check NVRO's competition here
Neuronetics, Inc. (NASDAQ: STIM)
BIO-B vs STIM Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, STIM has a market cap of 192.8M. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while STIM trades at $2.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas STIM's P/E ratio is -6.30. In terms of profitability, BIO-B's ROE is +0.03%, compared to STIM's ROE of -1.51%. Regarding short-term risk, BIO-B is less volatile compared to STIM. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check STIM's competition here
BioSig Technologies, Inc. (NASDAQ: BSGM)
BIO-B vs BSGM Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas BSGM's P/E ratio is -5.81. In terms of profitability, BIO-B's ROE is +0.03%, compared to BSGM's ROE of +15.26%. Regarding short-term risk, BIO-B is less volatile compared to BSGM. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check BSGM's competition here
Lucid Diagnostics Inc. (NASDAQ: LUCD)
BIO-B vs LUCD Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, LUCD has a market cap of 188.8M. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while LUCD trades at $0.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas LUCD's P/E ratio is -2.68. In terms of profitability, BIO-B's ROE is +0.03%, compared to LUCD's ROE of -4.04%. Regarding short-term risk, BIO-B is less volatile compared to LUCD. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check LUCD's competition here
Xylo Technologies Ltd. (NASDAQ: MDGS)
BIO-B vs MDGS Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas MDGS's P/E ratio is -0.27. In terms of profitability, BIO-B's ROE is +0.03%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, BIO-B is less volatile compared to MDGS. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check MDGS's competition here
Quipt Home Medical Corp. (NASDAQ: QIPT)
BIO-B vs QIPT Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while QIPT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas QIPT's P/E ratio is -15.87. In terms of profitability, BIO-B's ROE is +0.03%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, BIO-B is more volatile compared to QIPT. This indicates higher risk in terms of short-term price fluctuations for BIO-B.Check QIPT's competition here
EDAP TMS S.A. American Depositary Shares (NASDAQ: FOCL)
BIO-B vs FOCL Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, FOCL has a market cap of 158.2M. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while FOCL trades at $4.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas FOCL's P/E ratio is -4.08. In terms of profitability, BIO-B's ROE is +0.03%, compared to FOCL's ROE of -2.90%. Regarding short-term risk, BIO-B is less volatile compared to FOCL. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check FOCL's competition here
Quantum-Si incorporated (NASDAQ: QSI)
BIO-B vs QSI Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, QSI has a market cap of 150.5M. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while QSI trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas QSI's P/E ratio is -1.65. In terms of profitability, BIO-B's ROE is +0.03%, compared to QSI's ROE of -0.47%. Regarding short-term risk, BIO-B is less volatile compared to QSI. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check QSI's competition here
Inogen, Inc. (NASDAQ: INGN)
BIO-B vs INGN Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, INGN has a market cap of 145.9M. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while INGN trades at $5.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas INGN's P/E ratio is -5.92. In terms of profitability, BIO-B's ROE is +0.03%, compared to INGN's ROE of -0.13%. Regarding short-term risk, BIO-B is less volatile compared to INGN. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check INGN's competition here
Quanterix Corporation (NASDAQ: QTRX)
BIO-B vs QTRX Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, QTRX has a market cap of 122.9M. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while QTRX trades at $2.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas QTRX's P/E ratio is -1.03. In terms of profitability, BIO-B's ROE is +0.03%, compared to QTRX's ROE of -0.44%. Regarding short-term risk, BIO-B is less volatile compared to QTRX. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check QTRX's competition here
iCAD, Inc. (NASDAQ: ICAD)
BIO-B vs ICAD Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while ICAD trades at $3.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas ICAD's P/E ratio is -20.37. In terms of profitability, BIO-B's ROE is +0.03%, compared to ICAD's ROE of -0.18%. Regarding short-term risk, BIO-B is more volatile compared to ICAD. This indicates higher risk in terms of short-term price fluctuations for BIO-B.Check ICAD's competition here
LENSAR Inc (NASDAQ: LNSR)
BIO-B vs LNSR Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, LNSR has a market cap of 104.4M. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while LNSR trades at $8.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas LNSR's P/E ratio is 8.67. In terms of profitability, BIO-B's ROE is +0.03%, compared to LNSR's ROE of +103.80%. Regarding short-term risk, BIO-B is less volatile compared to LNSR. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check LNSR's competition here
Hancock Jaffe Laboratories (NASDAQ: HJLI)
BIO-B vs HJLI Comparison September 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 10.4B. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, BIO-B is priced at $381.37 on the NYSE, while HJLI trades at $10.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -67.15, whereas HJLI's P/E ratio is N/A. In terms of profitability, BIO-B's ROE is +0.03%, compared to HJLI's ROE of -0.62%. Regarding short-term risk, BIO-B is less volatile compared to HJLI. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check HJLI's competition here